Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Hepatitis C Antiviral Long-Term Treatment Against Cirrhosis Trial (HALT-C)

Trial Profile

Hepatitis C Antiviral Long-Term Treatment Against Cirrhosis Trial (HALT-C)

Phase of Trial: Phase III

Latest Information Update: 18 May 2018

At a glance

  • Drugs Peginterferon alfa-2a (Primary) ; Ribavirin
  • Indications Hepatitis C; Liver cirrhosis
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms HALT-C
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 01 Mar 2011 Tolerability results assessing the incidence of depression published in the Journal of Affective Disorders.
    • 08 Jun 2010 Planned number of patients changed from 1050 to 1350 as reported by Roche record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top